Activation of GSDMD contributes to acute kidney injury induced by cisplatin.
Cisplatin is one of the most effective antitumor agents, while the clinical use of which is highly limited by its severe side effects, especially the nephrotoxicity. Recently, the active form of gasdermin D (GSDMD), termed GSDMD-N, was identified to mediate pyroptotic inflammatory cell death in several diseases. However, the role of GSDMD-N fragment in cisplatin-induced AKI remains unclear. In this study, we found that pyroptosis was induced by cisplatin in both mouse kidney tissues and renal tubular epithelial cells (RTECs), accompanied by the increased expression of GSDMD-N fragment. In GSDMD-/- mice with cisplatin-induced AKI, we found that cisplatin-induced loss of renal function, renal tubular injury, and inflammation were all significantly attenuated compared with WT animals. Furthermore, GSDMD-N fragment was overexpressed by an established rapid plasmid tail-vein injection approach to evaluate the role of this cleaved form of GSDMD in AKI. As expected, mice with the GSDMD-N fragment overexpression in kidney were more susceptible to cisplatin induced AKI than the controls, evidenced by further elevated serum levels of BUN and Cr, aggravated renal pathology, increased expressions of NGAL and KIM-1,and enhanced renal inflammatory cytokine secretion, which indicates a pathogenic role of GSDMD-N in cisplatin-induced AKI by triggering cell pyroptosis. Similar results were also observed in RTECs by overexpressing GSDMD-N fragment. Thus, these findings suggested that the activation of GSDMD contributes to cisplatin-induced AKI possibly through triggering pyroptosis.